ANT-GROUP
5.7.2024 12:27:25 CEST | Business Wire | Press release
Ant Group today unveiled SecretFlow Cloud, its cloud-based cryptographic computing platform, and a suite of cryptographic computing solutions tailored for large language models (LLMs) at the World Artificial Intelligence Conference in Shanghai.
Leveraging integrated software-hardware cryptographic computing technologies, these solutions enable the secure circulation of encrypted data throughout the hosting and inference processes of LLMs, safeguarding the integrity of LLM assets and data security while significantly enhancing data privacy protection. Providers can now encrypt and deploy their LLMs onto cloud environments effortlessly with a single click through its encrypted hosting service, safeguarding their valuable assets from compromise and theft. Meanwhile, the encrypted inference service ensures efficient data security and the protection of trade secrets during interactions with LLMs.
These solutions allow GPUs to perform computing tasks within trusted execution environments, notably reducing the cost and performance disparity between encrypted LLM inference and plaintext operations, providing a more cost-effective approach. The platform also integrates additional technologies such as memory and disk encryption, ensuring end-to-end encryption and secure cross-domain model hosting management. Additionally, a user-friendly remote attestation system allows for smooth verification through web interfaces, minimizing friction for users.
SecretFlow Cloud currently supports both public and private cloud deployments, and is compatible with commonly-used LLMs in the global market. For instance, in a public cloud setup, users can seamlessly build a new professional LLM on SecretFlow Cloud or migrate an existing LLM to the platform, with its secure LLM inference services ready in as few as 10 minutes with just a click. Moreover, users can purchase cryptographic computing resources on demand to meet their needs.
"Data is the most critical element in the application of LLMs, and cryptographic computing technology significantly enhances the utility of data in cross-domain scenarios," noted Dr. Lenx Wei, Vice President and Chief Technology Security Officer at Ant Group. "As LLMs evolve toward specialized professional domains and become essential productivity tools, cryptographic computing will play a vital role, particularly in fully unlocking the value of high-quality, domain-specific data sets."
According to Dr. Wei, while companies often deploy LLMs in private environments to address data security challenges, such methods can incur higher operational costs and compromise both service efficiency and quality, ultimately constraining the potential of LLMs. The cryptographic computing solutions offered by SecretFlow Cloud can effectively resolve these issues.
Looking forward, SecretFlow Cloud aims to further develop its cryptographic computing solutions to ensure data security throughout the full lifecycle of professional LLMs, including their creation, deployment, and service delivery.
Ant Group has been exploring privacy-preserving computing technologies since 2016 and released SecretFlow in 2022 as an open-source privacy-preserving computing framework that features an array of advanced technologies, including multiparty computation, federated learning, Trusted Execution Environments, Homomorphic Encryption, and Differential Privacy. Positioned at the forefront of cryptographic computing, SecretFlow Cloud represents a new generation of privacy-preserving computing technology, poised to overcome pain points in security, cost, and accessibility in data circulation. It offers a solution for instantly harnessing data value, akin to turning on a tap. To date, its technologies have been adopted in industries such as insurance, rural finance, healthcare, public services, and marketing.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240705154761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
